WuXi Biologics

Corporate brand

WuXi Biologics is a global contract research, development and manufacturing organization focused on biologic medicines and related bioprocessing services.

Last updated October 14, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

WuXi Biologics is a China-based global contract research, development and manufacturing organization, commonly abbreviated as a CRDMO. The company provides integrated, open-access services for the discovery, development, testing, clinical manufacture and commercial production of biologic medicines. Its customers include biotechnology and pharmaceutical companies that outsource some or all of the technical and manufacturing work required to move biologic drug candidates from laboratory research through clinical trials and, in some cases, commercial supply. The business originated in 2010 as a biologics division of WuXi AppTec. Its early development centered on building capabilities in biologics discovery, cell-line development, process development, analytical testing and good manufacturing practice production. Unlike a conventional pharmaceutical company, WuXi Biologics generally operates as a service provider rather than marketing a broad proprietary portfolio of branded medicines. Its role is to supply platforms, scientific expertise, manufacturing capacity and regulatory-support capabilities to third-party drug developers. The company's service scope covers a wide range of biological modalities. These include monoclonal antibodies, recombinant proteins, antibody-drug conjugates, vaccines, plasmid DNA and other complex biologic products. Its offering extends from research and development work to drug-substance manufacturing, drug-product formulation, fill-finish, quality control and selected testing services. The company has promoted an integrated model intended to allow a customer to use one provider across multiple stages of a product's life cycle. WuXi Biologics was separated from WuXi AppTec and became a separately listed company on the Hong Kong Stock Exchange in June 2017. The listing created an independent public-market identity for the biologics-focused business while retaining its broader connection with the WuXi life-sciences group. In August 2020, the company became a constituent of Hong Kong's Hang Seng Index, reflecting its increased market visibility and scale at that time. International expansion has been a central part of the brand's development. The company established or planned manufacturing, development and testing operations in China, the United States, Ireland, Germany and Singapore. Its network has included Chinese facilities in cities such as Shanghai, Wuxi, Hangzhou, Suzhou, Chengdu and Shijiazhuang, as well as overseas sites in Dundalk, Leverkusen, Wuppertal, Worcester and Cranbury. The network was designed to provide geographically distributed capacity, local regulatory access and different production technologies, including single-use systems, fed-batch processing and continuous perfusion. WuXi Biologics' positioning is based on speed, technical breadth, manufacturing scale and an asset-light customer-access model. The company presents its facilities as open-access platforms that can support both emerging biotechnology companies and larger pharmaceutical groups. Acquisitions and site agreements have expanded its capabilities in fill-finish, drug-substance manufacturing, vaccine production and biosafety testing. Examples include transactions involving Pfizer's Hangzhou biotechnology center, CMAB Biopharma's Suzhou operations, and Bayer-related sites in Germany. The company has also faced heightened geopolitical and regulatory scrutiny. In 2024, proposed United States legislation targeting certain biotechnology companies, including WuXi Biologics, generated concern among investors and contributed to a sharp decline in the company's share price when the proposals became public. The debate focused on national-security concerns and alleged connections to China's military-civil fusion framework. WuXi Biologics denied the allegations described in the political criticism. The episode highlighted the strategic importance and political sensitivity of globally distributed contract manufacturing in the pharmaceutical supply chain. WuXi Biologics remains an active international CRDMO brand. Its identity is principally business-to-business: the company is usually encountered by drug developers, regulators and industry partners rather than by patients as a consumer-facing medicine brand. Its long-term significance depends on its ability to maintain regulatory compliance, add manufacturing capacity, serve complex biologic modalities and manage cross-border political and supply-chain risks.

History

WuXi Biologics traces its roots to 2010, when WuXi AppTec established a dedicated biologics division. The division was created to address the growing need for specialized external support in the discovery, development and manufacture of biological medicines. Biologics require different technologies, facilities and quality systems from conventional small-molecule pharmaceuticals, including mammalian-cell culture, complex analytical characterization, viral-safety controls and tightly controlled manufacturing processes. During its early development, the business built laboratories and manufacturing capabilities supporting biologics discovery, cell-line development, process development and good manufacturing practice production. Its model combined scientific services with manufacturing capacity, allowing customers to outsource work at multiple stages rather than engage separate providers for research, clinical supply and commercial production. The company later described this integrated structure as a CRDMO model, combining contract research, development and manufacturing. The biologics business was subsequently spun off from WuXi AppTec. WuXi Biologics completed its public listing on the Hong Kong Stock Exchange in June 2017, establishing an independent listed identity while remaining associated with the wider WuXi life-sciences group. The listing helped provide a separate capital base for expansion and supported the development of a larger international manufacturing network. Internationalization accelerated during the late 2010s and early 2020s. In China, the company operated or developed facilities in Shanghai, Wuxi, Hangzhou, Suzhou, Chengdu and Shijiazhuang. These sites supported different portions of the value chain, including research, antibody-drug conjugate work, biosafety testing, microbial fermentation, viral-vaccine production and large-scale biologics manufacturing. A Suzhou testing facility was described as one of the first non-government-affiliated biosafety testing facilities in Asia and provided services such as cell-line characterization, viral-clearance validation and unprocessed-bulk lot release. The company expanded outside China through greenfield projects, leases, acquisitions and strategic site agreements. In Singapore, it announced plans for a manufacturing facility with fed-batch and continuous-processing capacity. In Ireland, it developed a major Dundalk site for drug-substance manufacturing and later announced additional vaccine manufacturing investment through WuXi Vaccines. In Germany, agreements with Bayer involved a Leverkusen fill-finish operation and a Wuppertal drug-substance production site. In the United States, the company established or planned facilities in Massachusetts, New Jersey and Pennsylvania to provide clinical manufacturing and process-development capabilities. Several transactions broadened the network. In 2020, WuXi Biologics agreed with Bayer to take over operations and lease a Leverkusen fill site, which was intended to support final fill-finish for biologic products and provide backup capacity for Bayer's Kovaltry product. Later that year, the company announced a further agreement related to a Bayer drug-substance site in Wuppertal. In 2021, WuXi Biologics announced an equity agreement with Pfizer China concerning a Hangzhou biotechnology center and a purchase agreement with CBC Group concerning a controlling interest in CMAB Biopharma Group. These deals added manufacturing capacity and complementary development and testing capabilities. By 2021, the company reported a network of 18 manufacturing sites across China, the United States, Ireland, Germany and Singapore. Its facilities incorporated multiple production approaches, including single-use bioreactors, traditional fed-batch systems and continuous perfusion. The network was intended to serve both clinical and commercial programs and to provide customers with access to capacity close to major biopharmaceutical markets. WuXi Biologics' growth also brought geopolitical scrutiny. In January 2024, the company's shares declined after news that members of the United States Congress had introduced legislation seeking to prevent certain federal contracts with the company. Political criticism cited national-security concerns and allegations regarding cooperation with the People's Liberation Army within China's military-civil fusion framework. The company denied the allegations. Subsequent calls by members of the U.S. House Select Committee on Strategic Competition between the United States and the Chinese Communist Party for sanctions intensified attention on the company and on the broader dependence of pharmaceutical supply chains on China-linked service providers. The King of Prussia, Pennsylvania process-development site was subsequently identified for closure in 2024. This development occurred as WuXi Biologics continued to manage its international footprint amid changing demand, capacity planning and regulatory conditions. The company's history therefore combines rapid biologics outsourcing growth, international capacity expansion, acquisitions and partnerships, and increasing exposure to cross-border regulatory and political risk.

2024
U.S. biotechnology security legislation controversy
[1]WuXi Biologics - Wikipediaen.wikipedia.org
Proposed U.S. legislation targeting certain biotechnology companies intensified scrutiny of WuXi Biologics and affected its share price.
2021
Pfizer China Hangzhou transaction
[1]WuXi Biologics - Wikipediaen.wikipedia.org
WuXi Biologics announced an agreement to acquire Pfizer China's Hangzhou global biotechnology center and associated facilities.
2021
CMAB Biopharma transaction announced
[1]WuXi Biologics - Wikipediaen.wikipedia.org
WuXi Biologics announced an agreement to acquire a controlling interest in CMAB Biopharma Group and related Suzhou assets.
2020
Hang Seng Index inclusion
[1]WuXi Biologics - Wikipediaen.wikipedia.org
WuXi Biologics became a constituent of Hong Kong's Hang Seng Index in August.
2020
Bayer Leverkusen site agreement
[1]WuXi Biologics - Wikipediaen.wikipedia.org
WuXi Biologics agreed to take over operations and lease a Bayer fill-finish site in Leverkusen, Germany.
2020
Bayer Wuppertal site agreement
[1]WuXi Biologics - Wikipediaen.wikipedia.org
The company announced an agreement involving Bayer's drug-substance production site in Wuppertal, Germany.
2019
Additional Dundalk vaccine investment
[1]WuXi Biologics - Wikipediaen.wikipedia.org
WuXi Vaccines announced additional investment in a vaccine manufacturing facility at the Dundalk campus.
2018
Singapore manufacturing project announced
[1]WuXi Biologics - Wikipediaen.wikipedia.org
The company announced plans for a Singapore facility with fed-batch and continuous-processing bioreactor capacity.
2018
Dundalk drug-substance project announced
[1]WuXi Biologics - Wikipediaen.wikipedia.org
WuXi Biologics announced plans for a major biologics drug-substance manufacturing site in Dundalk, Ireland.
2017
Hong Kong public listing
[1]WuXi Biologics - Wikipediaen.wikipedia.org
WuXi Biologics was spun off and listed on the Hong Kong Stock Exchange in June.
2010
Biologics division established
[1]WuXi Biologics - Wikipediaen.wikipedia.org
WuXi AppTec established the biologics business that later became WuXi Biologics.

Products and positioning

A global, integrated and open-access CRDMO for biologic medicines, positioned around scientific breadth, rapid development, flexible manufacturing capacity and support across the full product life cycle.

Contract research, development and manufacturing
Integrated biologics CRDMO services
The company's core offering combines discovery support, cell-line and process development, analytical work, clinical manufacturing and commercial production. The integrated model is intended to reduce handoffs between service providers and give customers access to a coordinated technical and quality system across the biologic product life cycle.
Biologics development and manufacturing
Monoclonal antibody services
WuXi Biologics develops and manufactures antibody-based medicines for external customers. Services can span cell-line development, upstream and downstream process work, analytical characterization, clinical drug substance and drug product, and larger-scale production subject to facility and regulatory requirements.
Biologics development and manufacturing
Recombinant protein services
The company supports recombinant-protein programs through development and manufacturing capabilities. Its Hangzhou operations were described as supporting recombinant proteins and plasmid DNA produced through microbial fermentation, alongside other biologics activities.
Advanced biologics
Antibody-drug conjugate services
WuXi Biologics provides development and production support for antibody-drug conjugates, a complex class of medicines combining an antibody with a therapeutic payload. Its Wuxi New Area operations include laboratories associated with antibody-drug conjugate development and production.
Vaccines
Vaccine manufacturing
Through WuXi Vaccines and related biologics capabilities, the group develops vaccine manufacturing infrastructure covering drug substance, drug product, manufacturing science and technology, and quality-control functions. The Dundalk project was designed to support vaccine production for an unidentified global vaccine customer.
Biological materials
Plasmid DNA manufacturing
The company has described capabilities for the development and good manufacturing practice manufacture of plasmid DNA, including activity associated with its Hangzhou facilities. Plasmid DNA can serve as a raw material or intermediate for selected biologic and vaccine applications.
Laboratory and quality services
Biosafety and viral-clearance testing
WuXi Biologics operates testing and characterization capabilities covering cell-line characterization, viral-clearance validation and unprocessed-bulk lot release. These services help customers demonstrate control of biologic manufacturing processes and address regulatory expectations for viral safety and product quality.
Pharmaceutical manufacturing
Fill-finish and drug-product services
The company's network includes liquid and lyophilized drug-product operations and fill-finish facilities. The Leverkusen site in Germany was intended to perform final fill-finish for biologics and provide additional filling support for selected products.

Controversies

2024
U.S. national-security and military-civil-fusion allegations
U.S. lawmakers introduced legislation that could restrict federal contracts with WuXi Biologics and other biotechnology companies amid national-security concerns. The criticism included allegations that WuXi Biologics had worked closely with the People's Liberation Army as part of China's military-civil fusion strategy. The company denied the allegations. The controversy led to calls by members of a U.S. House select committee for sanctions and contributed to market pressure on the company.
Source

2024
Close the King of Prussia process-development siteStrategy
Background
WuXi Biologics continued to adjust its international site portfolio amid changing capacity and operating requirements.
Action taken
The company announced that its King of Prussia, Pennsylvania process-development site would cease operations.
Aftermath
The closure reduced part of the company's U.S. laboratory footprint while geopolitical scrutiny of China-linked biotechnology suppliers was increasing.
Source
2021
Add Hangzhou and Suzhou capabilitiesM&A
Background
The company was expanding its Chinese development and manufacturing platform across different biologic modalities.
Action taken
WuXi Biologics announced the Pfizer China Hangzhou transaction and an agreement to acquire a controlling interest in CMAB Biopharma Group.
Aftermath
The transactions were intended to add recombinant-protein, plasmid-DNA, vaccine, bioreactor, fill-finish and related biologics capabilities.
Source
2020
Expand through Bayer site transactionsM&A
Background
WuXi Biologics sought additional European drug-product and drug-substance manufacturing capacity.
Action taken
The company announced agreements involving Bayer's Leverkusen fill-finish site and Wuppertal drug-substance site.
Aftermath
The agreements added European manufacturing assets and supported the company's regional supply capabilities.
Source
2018
Build an international manufacturing networkStrategy
Background
Biopharmaceutical customers increasingly sought geographically distributed capacity and access to local development and manufacturing infrastructure.
Action taken
The company announced manufacturing projects in Singapore and Ireland, adding to its Chinese network.
Aftermath
The planned facilities broadened the company's international footprint and its ability to support overseas customers.
Source
2017
Separate the biologics business and pursue a public listingStrategy
Background
The biologics division had developed into a specialized service business within WuXi AppTec.
Action taken
WuXi Biologics was spun off and listed on the Hong Kong Stock Exchange in June 2017.
Aftermath
The transaction created an independent listed platform for expanding the biologics-focused CRDMO network.
Source

Recent events

Unconfirmed
Immune-Onc completes approximately $73 million funding round[5]Immune-Onc完成约7300万美元融资finance.sina.com.cn
Reported: 2021-03-30
Immune-Onc completed a B1/B2 funding round of approximately $73 million, led by Haisong Capital, with other investors also participating. The funds are primarily for advancing and expanding its drug pipeline globally and supporting operations in the United States and China.
2021-02-24
WuXi Biologics wins 2021 CMO Leadership Awards[6]药明生物荣获2021年CMO领导力奖prnasia.com
Reported: 2021-02-25
WuXi Biologics was named a winner of the 2021 CMO Leadership Awards in all six core categories and across the Big Pharma, Small Pharma, and Overall respondent groups.
2021-02-08
WuXi Biologics launches GMP operation at MFG5[7]药明生物MFG5设施启动GMP运营prnewswire.com
Reported: 2021-02-09
WuXi Biologics launched GMP operation at its MFG5 drug-substance manufacturing facility in China, which has a capacity of 36,000 liters and brought the company’s current capacity to 90,000 liters.
2020-12-28
WuXi Biologics received GMP certification from Brazil's ANVISA[8]药明生物获得巴西ANVISA的GMP认证prnewswire.com
Reported: 2020-12-28
WuXi Biologics announced that it had received Good Manufacturing Practice certification from Brazil's Agência Nacional de Vigilância Sanitária (ANVISA).
2020-05-18
WuXi Biologics signs land deal for Worcester manufacturing facility[9]药明生物签署伍斯特生产设施土地交易协议prnewswire.com
Reported: 2020-05-19
WuXi Biologics and the Worcester Business Development Corporation announced the signing of a land deal for WuXi Biologics' clinical and commercial manufacturing facility in Worcester. The facility was planned to become operational in 2022 and create 150 jobs.
2020-04-21
WuXi Biologics completed acquisition of Bayer manufacturing plant[10]药明生物完成收购拜耳制造工厂prnewswire.com
Reported: 2020-04-22
WuXi Biologics announced that it completed the acquisition of a drug product manufacturing plant in Leverkusen, Germany, from Bayer. WuXi Biologics took over plant operations and purchased the plant equipment.
2020-02-25
WuXi Biologics and Vir Biotechnology partner on COVID-19 antibody development and production[11]药明生物与Vir Biotechnology合作开发和生产新冠抗体prnasia.com
Reported: 2020-02-25
WuXi Biologics and Vir Biotechnology announced a collaboration agreement to develop and produce fully human monoclonal antibodies for treating COVID-19. WuXi Biologics will support cell-line, process and formulation development and early clinical production; the agreement provides WuXi Biologics commercialization rights in Greater China if the antibodies receive regulatory approval, while Vir holds rights in other global markets.
2019-12-23
WuXi Biologics receives Ireland investor award[12]WuXi Biologics获得爱尔兰投资者特别奖prnewswire.com
Reported: 2019-12-23
WuXi Biologics announced that it received the “Special Award to Investors in Ireland” at the 2019 Global Business Summit held by Asia Matters.
2019-12-19
WuXi Biologics and Convalife partner on bispecific antibody development[13]药明生物与甫康健康科技合作开发双特异性抗体prnasia.com
Reported: 2019-12-18
WuXi Biologics and Convalife announced a collaboration to develop an innovative anti-tumor bispecific antibody. Convalife will use WuXi Biologics' integrated biopharmaceutical capabilities, while WuXi Biologics will provide technical support for discovery, development and manufacturing.
2019-10-16
WuXi Biologics and Newcode Therapeutics partner on ARX788 development and production[14]药明生物与新码生物就ARX788研发及生产达成战略合作finance.sina.com.cn
Reported: 2019-10-16
WuXi Biologics and Newcode Therapeutics announced a strategic collaboration supporting ARX788's phase III clinical research and large-scale commercial production. WuXi Biologics will provide drug-substance and drug-product work for phase III clinical samples, process characterization and validation, and large-scale commercial production services.

Showing the 10 most recent.

Sources18 sources

Cite this profile: Cite the canonical profile. /brand-wiki/wuxi-biologics · Editorial policy · How profiles are compiled